Equities Analysts Offer Predictions for Geron Q3 Earnings

Key Points

• Leerink Partners has increased their Q3 2025 earnings estimate for Geron Corporation from ($0.05) to ($0.04) per share, indicating improved expectations for the biopharmaceutical company.
• Geron recently reported earnings of ($0.02) per share for the quarter, surpassing analysts' consensus estimates and generating $49.04 million in revenue, which is a significant year-over-year increase of 5455.6%.
• Institutional investors own about 73.71% of Geron’s stock, with notable increases in holdings from RA Capital Management and Vanguard Group in recent quarters.

Geron Corporation (NASDAQ:GERN - Free Report) - Equities researchers at Leerink Partnrs upped their Q3 2025 earnings per share (EPS) estimates for shares of Geron in a research report issued on Wednesday, August 6th. Leerink Partnrs analyst F. Khurshid now anticipates that the biopharmaceutical company will earn ($0.04) per share for the quarter, up from their prior forecast of ($0.05). The consensus estimate for Geron's current full-year earnings is ($0.25) per share. Leerink Partnrs also issued estimates for Geron's Q4 2025 earnings at ($0.04) EPS and FY2025 earnings at ($0.13) EPS.

Other equities analysts also recently issued research reports about the company. Scotiabank downgraded Geron from a "sector outperform" rating to a "sector perform" rating and reduced their price objective for the stock from $4.00 to $1.50 in a research report on Thursday, May 8th. The Goldman Sachs Group initiated coverage on Geron in a research note on Thursday, July 10th. They set a "sell" rating and a $1.00 target price for the company. One research analyst has rated the stock with a sell rating, three have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $4.19.

Geron Price Performance

GERN stock traded up $0.02 during mid-day trading on Monday, reaching $1.45. 3,361,002 shares of the company's stock were exchanged, compared to its average volume of 12,737,896. The company has a market cap of $921.94 million, a price-to-earnings ratio of -11.12 and a beta of 0.73. The stock's 50 day moving average is $1.38 and its 200 day moving average is $1.64. Geron has a 12-month low of $1.09 and a 12-month high of $4.83. The company has a debt-to-equity ratio of 0.46, a current ratio of 7.87 and a quick ratio of 6.79.

Geron (NASDAQ:GERN - Get Free Report) last posted its earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.01. The firm had revenue of $49.04 million for the quarter, compared to analyst estimates of $47.30 million. Geron had a negative return on equity of 31.37% and a negative net margin of 53.52%. Geron's revenue for the quarter was up 5455.6% compared to the same quarter last year. During the same period last year, the company earned ($0.10) earnings per share.

Hedge Funds Weigh In On Geron

A number of large investors have recently modified their holdings of GERN. Frisch Financial Group Inc. raised its stake in shares of Geron by 84.3% during the 1st quarter. Frisch Financial Group Inc. now owns 19,025 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 8,700 shares in the last quarter. StoneCrest Wealth Management Inc. acquired a new stake in shares of Geron in the 2nd quarter worth approximately $35,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Geron in the 4th quarter worth approximately $36,000. Savant Capital LLC grew its holdings in shares of Geron by 73.8% in the 2nd quarter. Savant Capital LLC now owns 26,074 shares of the biopharmaceutical company's stock worth $37,000 after acquiring an additional 11,074 shares during the period. Finally, Summit Financial Strategies Inc. acquired a new stake in shares of Geron in the 2nd quarter worth approximately $38,000. 73.71% of the stock is owned by hedge funds and other institutional investors.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.